生产人类肿瘤靶标极光激酶 b 与其结合伙伴 incenp 复合物的稳健方法。

Jonna Mattsson, Per Rogne, Maréne Landström, Magnus Wolf-Watz
{"title":"生产人类肿瘤靶标极光激酶 b 与其结合伙伴 incenp 复合物的稳健方法。","authors":"Jonna Mattsson, Per Rogne, Maréne Landström, Magnus Wolf-Watz","doi":"10.1016/j.biochi.2024.10.011","DOIUrl":null,"url":null,"abstract":"<p><p>Protein kinases are key players in many eukaryotic signal transduction cascades and are as a result often linked to human disease. In humans, the mitotic protein kinase family of Aurora kinases consist of three members: Aurora A, B and C. All three members are involved in cell division with proposed implications in various human cancers. The human Aurora kinase B has in particular proven challenging to study with structural biology approaches, and this is mainly due to difficulties in producing the large quantities of active enzyme required for such studies. Here, we present a novel and E. coli-based production system that allows for production of milligram quantities of well-folded and active human Aurora B in complex with its binding partner INCENP. The complex is produced as a continuous polypeptide chain and the resulting fusion protein is cleaved with TEV protease to generate a stable and native heterodimer of the Aurora B:INCENP complex. The activity, stability and degree of phosphorylation of the protein complex was quantified by using a coupled ATPase assay, <sup>31</sup>P NMR spectroscopy and mass spectrometry. The developed production system enables isotope labeling and we here report the first <sup>1</sup>H-<sup>15</sup>N-HSQC of the human Aurora B:INCENP complex. Our developed production strategy paves the way for future structural and functional studies of Aurora B and can as such assist the development of novel anticancer drugs targeting this important mitotic protein kinase.</p>","PeriodicalId":93898,"journal":{"name":"Biochimie","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Robust approach for production of the human oncology target Aurora kinase B in complex with its binding partner INCENP.\",\"authors\":\"Jonna Mattsson, Per Rogne, Maréne Landström, Magnus Wolf-Watz\",\"doi\":\"10.1016/j.biochi.2024.10.011\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Protein kinases are key players in many eukaryotic signal transduction cascades and are as a result often linked to human disease. In humans, the mitotic protein kinase family of Aurora kinases consist of three members: Aurora A, B and C. All three members are involved in cell division with proposed implications in various human cancers. The human Aurora kinase B has in particular proven challenging to study with structural biology approaches, and this is mainly due to difficulties in producing the large quantities of active enzyme required for such studies. Here, we present a novel and E. coli-based production system that allows for production of milligram quantities of well-folded and active human Aurora B in complex with its binding partner INCENP. The complex is produced as a continuous polypeptide chain and the resulting fusion protein is cleaved with TEV protease to generate a stable and native heterodimer of the Aurora B:INCENP complex. The activity, stability and degree of phosphorylation of the protein complex was quantified by using a coupled ATPase assay, <sup>31</sup>P NMR spectroscopy and mass spectrometry. The developed production system enables isotope labeling and we here report the first <sup>1</sup>H-<sup>15</sup>N-HSQC of the human Aurora B:INCENP complex. Our developed production strategy paves the way for future structural and functional studies of Aurora B and can as such assist the development of novel anticancer drugs targeting this important mitotic protein kinase.</p>\",\"PeriodicalId\":93898,\"journal\":{\"name\":\"Biochimie\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-10-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Biochimie\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/j.biochi.2024.10.011\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biochimie","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.biochi.2024.10.011","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

蛋白激酶是许多真核生物信号转导级联中的关键角色,因此常常与人类疾病相关。在人类中,有丝分裂蛋白激酶家族中的极光激酶由三个成员组成:所有这三个成员都参与细胞分裂,并对各种人类癌症产生影响。事实证明,用结构生物学方法研究人类极光激酶 B 尤其具有挑战性,这主要是由于难以生产此类研究所需的大量活性酶。在这里,我们展示了一种基于大肠杆菌的新型生产系统,该系统可以生产折叠良好、具有活性的人极光激酶 B 与其结合伙伴 INCENP 复合物的毫克级数量。该复合物以连续多肽链的形式产生,产生的融合蛋白经 TEV 蛋白酶裂解后生成稳定的 Aurora B:INCENP 复合物异源二聚体。利用耦合 ATPase 分析法、31P NMR 光谱法和质谱法对蛋白复合物的活性、稳定性和磷酸化程度进行了量化。开发的生产系统可以进行同位素标记,我们在此首次报告了人类 Aurora B:INCENP 复合物的 1H-15N-HSQC 结果。我们开发的生产策略为今后 Aurora B 的结构和功能研究铺平了道路,从而有助于开发针对这一重要有丝分裂蛋白激酶的新型抗癌药物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Robust approach for production of the human oncology target Aurora kinase B in complex with its binding partner INCENP.

Protein kinases are key players in many eukaryotic signal transduction cascades and are as a result often linked to human disease. In humans, the mitotic protein kinase family of Aurora kinases consist of three members: Aurora A, B and C. All three members are involved in cell division with proposed implications in various human cancers. The human Aurora kinase B has in particular proven challenging to study with structural biology approaches, and this is mainly due to difficulties in producing the large quantities of active enzyme required for such studies. Here, we present a novel and E. coli-based production system that allows for production of milligram quantities of well-folded and active human Aurora B in complex with its binding partner INCENP. The complex is produced as a continuous polypeptide chain and the resulting fusion protein is cleaved with TEV protease to generate a stable and native heterodimer of the Aurora B:INCENP complex. The activity, stability and degree of phosphorylation of the protein complex was quantified by using a coupled ATPase assay, 31P NMR spectroscopy and mass spectrometry. The developed production system enables isotope labeling and we here report the first 1H-15N-HSQC of the human Aurora B:INCENP complex. Our developed production strategy paves the way for future structural and functional studies of Aurora B and can as such assist the development of novel anticancer drugs targeting this important mitotic protein kinase.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信